Powered by

Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy

Jan 17, 2019 - Business Wire

Omeros Corporation (Nasdaq: OMER) today announced that it has finalized its clinical plan for OMS721 submission and approval in immunoglobulin A nephropathy (IgAN) following a recent meeting with the U.S. Food and Drug Administration (FDA). OMS721 is Omeros' lead human monoclonal antibody targeting MASP-2, the effector enzyme of the complement system's lectin pathway. There is no approved treatment for IgA nephropathy.

FDA Meeting UpdateClinical results from the first and second cohorts of...